1. Chang YM, Kung HJ, Evans CP (2007) Nonreceptor tyrosine kinases in prostate cancer. Neoplasia 9:90–100
2. Kung H, Tepper C, de Vere WR (2001) Tyrosine kinases and cellular signaling in prostate cancer. In: Chung LWK, Isaacs W, Simons J (eds) Prostate cancer: biology, genetics and the new therapeutics. Humana Press, Inc., New Jersey, pp 241–266
3. Robinson D, He F, Pretlow T, Kung HJ (1996) A tyrosine kinase profile of prostate carcinoma. Proc Natl Acad Sci USA 93:5958– 5962
4. Damon SE, Plymate SR, Carroll JM et al (2001) Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinology 142:21–27
5. Davies G, Jiang WG, Mason MD (2001) HGF/SF modifies the interaction between its receptor c-Met, and the E-cadherin/catenin complex in prostate cancer cells. Int J Mol Med 7:385–388
6. Kwabi-Addo B, Ropiquet F, Giri D, Ittmann M (2001) Alternative splicing of fibroblast growth factor receptors in human prostate cancer. Prostate 46:163–172
7. Gimm O, Armanios M, Dziema H, Neumann HP, Eng C (2000) Somatic and occult germ-line mutations in SDHD, a mitochon- drial complex II gene, in nonfamilial pheochromocytoma. Cancer Res 60:6822–6825
8. Ricciardelli C, Jackson MW, Choong CS et al (2008) Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate 68:830–838
9. Shiozawa Y, Pedersen EA, Patel LR et al (2010) GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 12:116–127
10. Thobe MN, Gurusamy D, Pathrose P, Waltz SE (2010) The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells. Oncogene 29:214–226
11. Wiesner C, Nabha SM, Dos Santos EB et al (2008) C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. Neoplasia 10:996–1003
12. Culig Z, Hobisch A, Cronauer MV et al (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474–5478
13. Maecker HL, Yun Z, Maecker HT, Giaccia AJ (2002) Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2:139–148
14. Craft N, Shostak Y, Carey M, Sawyers CL (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280–285
15. Gregory CW, Whang YE, McCall W et al (2005) Heregulin- induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 11:1704–1712
16. Wen Y, Hu MC, Makino K et al (2000) HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 60:6841–6845
17. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C (1999) From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 96:5458–5463
18. Jiang X, Borgesi RA, McKnight NC, Kaur R, Carpenter CL, Balk SP (2007) Activation of nonreceptor tyrosine kinase Bmx/ Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells. J Biol Chem 282:32689–32698
19. Soler M, Mancini F, Meca-Cortes O et al (2009) HER3 is required for the maintenance of neuregulin-dependent and independent attributes of malignant progression in prostate cancer cells. Int J Cancer 125:2565–2575
20. Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ (1997) ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene 15:2705–2716
21. Qiu Y, Ravi L, Kung HJ (1998) Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 393:83–85
22. Wu YM, Robinson DR, Kung HJ (2004) Signal pathways in upregulation of chemokines by tyrosine kinase MER/NYK in prostate cancer cells. Cancer Res 64:7311–7320
23. Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE (2010) Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Oncogene 29:3208–3216
24. Dawson DM, Lawrence EG, MacLennan GT et al (1998) Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer. J Natl Cancer Inst 90:519–523
25. Encinas M, Crowder RJ, Milbrandt J, Johnson EM Jr (2004) Tyrosine 981, a novel ret autophosphorylation site, binds c-Src to mediate neuronal survival. J Biol Chem 279:18262–18269
26. Paronetto MP, Farini D, Sammarco I et al (2004) Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer. Am J Pathol 164:1243–1251
27. Marelli MM, Moretti RM, Procacci P, Motta M, Limonta P (2006) Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the alphavbeta3 integrin and PI3-K/Akt signaling. Int J Oncol 28:723–730
28. Hagmar L, Stromberg U, Bonassi S et al (2004) Impact of types of lymphocyte chromosomal aberrations on human cancer risk: results from Nordic to Italian cohorts. Cancer Res 64:2258–2263